A Phase 4 interventional study of Single-syringe Adenosine and Double Syringe Adenosine in Supraventricular Tachycardia, Supraventricular Tachycardias and Supraventricular Arrhythmia, sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Hormozgan University of Medical Sciences · Phase 4, Interventional, and Treatment
The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable paroxysmal supraventricular tachycardia (PSVT).
The American Heart Association 2015 guidelines recommend adenosine for non-hypotensive patients with regular narrow complex PSVT. Adenosine is usually given as a rapid intravenous bolus of 6mg over 1-2 seconds, followed by a 20ml saline flush. If the first dose does not result in the termination of PSVT to normal sinus rhythm (NSR) within 1-2 minutes, a repeat dose of 12mg can be given, and the dose may be repeated one more time, if necessary, for a total of three doses.
The double-syringe technique (DST) is the standard method for administering adenosine. However, recent studies suggest that the single-syringe technique (SST) may be simpler and potentially beneficial. This technique injects adenosine and saline simultaneously at the same time instead of two separate injections. The study aims to compare the efficacy of SST and DST method for PSVT termination.
73 studies on the registry are indexed under Tachycardia, Supraventricular; 22 are open to participants now.
This study's enrollment of 134 is above the median of 117 across 42 interventional studies indexed under Tachycardia, Supraventricular.
Browse Tachycardia, Supraventricular studies →Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Single-syringe Adenosine
Drug: Double Syringe Adenosine
Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 16 mL NS. A total of three doses could be provided to each patient
One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 16 mL NS. A total of three doses could be provided to each
First-dose Successful Termination of PSVT
Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.
Time frame: Within 2 minutes after administration of the first dose of adenosine.
Total Administered Dose of Adenosine.
Total cumulative dose of adenosine (mg) administered to achieve termination of PSVT.
Time frame: From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.
| Milestone | Single-syringe Technique (SST) | Double-syringe Technique (DST) |
|---|---|---|
| Started | 66 | 68 |
| Completed | 66 | 68 |
| Not completed | 0 | 0 |
Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.
| Participants | Single-syringe Technique (SST) | Double-syringe Technique (DST) |
|---|---|---|
| First-dose Successful Termination of PSVT | 50 | 39 |
Total cumulative dose of adenosine (mg) administered to achieve termination of PSVT.
| mg | Single-syringe Technique (SST) | Double-syringe Technique (DST) |
|---|---|---|
| Total Administered Dose of Adenosine. | 9.64 ± 6.97 | 12.71 ± 8.64 |
Collected over After adenosine administration, all patients were observed for adverse events, including hypotension, dyspnea, flushing, bradycardia, and chest pain. Monitoring was performed every 15 minutes for a duration of 30 to 60 minutes post-administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-syringe Technique (SST) | 0/66 (0%) | 0/66 (0%) | 4/66 (6.1%) |
| Double-syringe Technique (DST) | 0/68 (0%) | 0/68 (0%) | 25/68 (36.8%) |
| Event | Single-syringe Technique (SST) | Double-syringe Technique (DST) |
|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 3/66 | 18/68 |
| Chest painCardiac disorders | 0/66 | 10/68 |
| HypotensionCardiac disorders | 1/66 | 1/68 |
| FlushingSkin and subcutaneous tissue disorders | 0/66 | 1/68 |
| BradycardiaCardiac disorders | 0/66 | 0/68 |
| Age, Continuous(Years) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Mean | 45.03 ± 13.82 | 52.27 ± 14.04 | 48.70 ± 14.35 |
| Sex: Female, Male(Participants) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Female | 33 | 34 | 67 |
| Male | 33 | 34 | 67 |
| Race and Ethnicity Not Collected(Participants) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Iran | 66 | 68 | 134 |
| Body mass index(Kg/m2) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Mean | 26.67 ± 4.21 | 26.51 ± 4.80 | 26.59 ± 4.50 |
| Baseline systolic blood pressure(mmHg) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Mean | 126.42 ± 19.27 | 123.98 ± 16.04 | 125.18 ± 17.68 |
| Baseline diastolic blood pressure(mmHg) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Mean | 77.60 ± 14.53 | 75.00 ± 13.34 | 76.28 ± 13.95 |
| Baseline heart rate(bpm) | Single-syringe Technique (SST) | Double-syringe Technique (DST) | Total |
|---|---|---|---|
| Mean | 169.01 ± 20.16 | 169.05 ± 19.93 | 169.03 ± 19.97 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tachycardia, Supraventricular →
Hormozgan University of Medical Sciences